A Study Using Radiation Therapy and Temozolomide to Treat Glioblastoma in Patients Over 70

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

May 31, 2025

Study Completion Date

May 31, 2025

Conditions
Glioblastoma
Interventions
RADIATION

Hypofractionated radiotherapy

Treatment of 3.4 Gy will be given daily 5 days per week over 2 weeks.

DRUG

Temozolomide

During concomitant phase Temozolomide will be administered orally at 75 mg/m2 for 2 weeks concomitant with radiotherapy. During the adjuvant phase Temozolomide will be administered orally at 150 mg/m2 on days 1 through day 5 of each 28 day cycle for a maximum of 6 cycles.

Trial Locations (1)

40202

James Graham Brown Cancer Center, Louisville

All Listed Sponsors
collaborator

James Graham Brown Cancer Center

OTHER

lead

University of Louisville

OTHER